In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Fact checked by Nick Blackmer For every health concern, someone on social media is touting a quick-fix solution—often in the ...

People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Mounjaro (tirzepatide) is a prescription drug that’s used to treat type 2 diabetes. The drug comes as a liquid solution that you inject under your skin, typically once per week. Mounjaro ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

A mom of two is getting her exercise by cleaning her house. It's something Melissa Floro says she didn't have the energy to ...

The best companies will pay you to own them, sharing their profits via dividends. These high-quality stocks continuously grow ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...